Disclaimer: yes, I ran this through AI to clean it up. Trust me you’d complain a lot more if you had to read my original shit sentences..

I’ve been digging through the smaller AI/data-center names, and AIB is one that still looks unusually cheap to me relative to what has changed over the last few weeks.

At around $1.39/share, AIB is valued at roughly $105M.

At June 30, the company reported $52.8M in cash.

Since then, AIB has signed Nebius for 50 MW of critical IT capacity under a 12-year agreement that AIB values at approximately $1.32B over the initial term.

So you have a company with roughly a $105M equity value, a last-reported cash balance equal to about half of that, and a signed AI data-center contract worth more than 12x the current market cap.

That obviously does not mean AIB is worth $1.32B. The project still needs to be financed, built and operated.

But I think the valuation setup is hard to ignore.

The Nebius deal changes AIB quite a bit

Before Nebius, AIB was mostly a power-and-development story.

They had sites, utility capacity and plans to attract AI/HPC customers, but there was still a big question:

Could they actually land a serious tenant?

Now they have 50 MW contracted to Nebius for an initial 12-year term, with two additional five-year renewal options.

The basic AIB model now looks pretty simple:

Secure power → sign AI/HPC customer → finance project → build capacity → collect long-term contracted revenue

CLT1 is the first real test of whether that model works.

The customer side has already been substantially de-risked.

The power position is probably the most important asset

Anyone following the AI infrastructure buildout knows how difficult it has become to secure meaningful amounts of power on useful timelines.

At CLT1, AIB has 65 MW of contracted utility power.

Fifty MW of that is now committed to Nebius.

AIB also acquired a Texas site with 15 MW of existing primary electric service plus up to another 40 MW under a utility facilities agreement.

That gives AIB roughly:

65 MW at CLT1

plus

55 MW at Texas

or about 120 MW of existing/contracted utility capacity across the two sites.

I would not value all 120 MW equally.

The 50 MW tied to Nebius is clearly worth more today because there is already a customer attached.

But the Texas site gives AIB another meaningful block of power to market.

If they sign another credible AI/HPC tenant there, I think that becomes a very important catalyst.

The financing structure may be just as important as the contract

The obvious question is how a company this small builds a project this large.

AIB says the Nebius agreement includes significant customer funding support, including contractual prepayments expected to fund a meaningful portion of CLT1’s initial development.

Management has also said that, based on the current development plan, AIB does not currently anticipate requiring corporate-level common equity to fund CLT1.

That statement matters a lot to me.

It does not mean dilution is impossible.

It does not mean all of the financing risk is gone.

But there is a huge difference between:

raising hundreds of millions through common stock

and

using customer prepayments plus project-level financing backed by a 12-year contract.

If AIB can build CLT1 without heavily diluting existing shareholders, I think the current valuation becomes much harder to justify.

The timeline is not that far away

AIB plans to deliver CLT1 in phases.

The first data hall is expected to provide approximately 25 MW of critical IT capacity, followed by another 25 MW in the second phase.

That matters because AIB does not have to wait for the entire 50 MW project to be finished before the story starts changing.

The next major step is simply proving they can move from:

signed contract

to

financed construction

to

operating capacity

If they deliver that first 25 MW, the company becomes a very different business than the one the market was valuing before the Nebius deal.

The balance sheet gives them some breathing room

At June 30, AIB reported roughly $52.8M in cash, $90.4M in total assets, $7.7M in total liabilities and $82.7M in shareholders’ equity.

The $52.8M cash figure is obviously not the exact cash balance today. AIB has used cash since then, including for the Texas acquisition.

Still, relative to a roughly $105M market cap, it is a meaningful starting position.

AIB also disclosed 75,979,466 common shares outstanding.

Including warrants, equity-plan shares and potential earnout shares, the company showed an illustrative fully diluted count of roughly 88.9M shares.

So dilution is something I would absolutely keep an eye on.

But even on a fully diluted basis, the valuation still looks small relative to the opportunity if CLT1 gets built successfully.

Texas may be the next important piece

AIB paid approximately $17.225M for the Texas acquisition.

The site has 15 MW of existing utility service plus up to another 40 MW under the facilities agreement.

So potentially 55 MW.

Right now, Texas does not have an announced Nebius-type tenant.

That is why I would not give those MW the same value as the contracted CLT1 capacity.

But if AIB signs another serious customer against Texas, the thesis gets a lot more interesting.

At that point Nebius no longer looks like a one-off deal.

It starts to look like AIB may have a repeatable model for converting secured power into long-term AI infrastructure contracts.

The risks

This is still a small-cap infrastructure company trying to execute a very large project.

The main risks I see are:

• Construction delays
• Cost overruns
• Project financing risk
• Future dilution
• Heavy reliance on Nebius
• Failure to deliver CLT1 on schedule
• Giving too much value to development-stage power before customers are signed

So this is definitely not a low-risk stock.

The next year should tell us a lot.

Why I think AIB is interesting

The market still seems to be valuing AIB much closer to the company it was before Nebius.

But the company now has:

50 MW contracted to Nebius

12-year initial term

two additional five-year renewal options

$1.32B of disclosed initial contract value

65 MW of contracted utility power at CLT1

another potential 55 MW at the Texas site

and a $52.8M last-reported cash balance.

Most importantly, management says corporate-level common equity is not currently expected to be required to fund CLT1.

For me, the thesis comes down to three things:

1. Finance CLT1 without crushing shareholders

2. Deliver the first 25 MW to Nebius

3. Sign another credible tenant against the remaining power portfolio

If they can do those three things, I think AIB gets valued very differently than it is today.

They do not have to become the next CoreWeave.

They just have to prove the model works.

Disclosure: I own shares of AIB.

Not financial advice. Small-cap infrastructure stocks carry significant execution, financing and dilution risk.

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

Stock are watching . J-Star Holding Co., Ltd. Highlights Capital Initiatives to Fund Planned U.S. Expansion for Drone Frame Manufacturing in Houston, Texas
HOUSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (NASDAQ: YMAT) ("J-Star" or the "Company"), an advanced composite manufacturing innovator, today announced that its ongoing corporate capital initiatives are strategically designed to fund the upcoming establishment of its automated carbon fiber production facility in Houston, Texas.

Herbal Dispatch (CSE: HERB / OTCQB: LUFFF) is still priced like a dead rec ticker. Q2 already showed the mix shift, they guided the next quarter to the inflection, and that quarter is now in the books.

What showed up in Q2:

• Gross profit up 74% to $0.75M even with lower overall revenue. They gave up top line on purpose.
• Gross margin 28.8% vs 15.7% in Q2 last year. First half also improved, 24.2% vs 20.0%.
• Medical more than doubled to $0.9M. YTD medical $1.5M vs $0.75M. Veteran channel at roughly a $2.2M annualized run rate. Insured, recurring, and management has previously pointed at 50%+ margins and about $6–7k annual spend per veteran patient.
• Exports +45% year over year to $0.7M. Q1 was a timing hole ($71k). Q2 is when the shipments landed.
• Exclusive EU-GMP processing deal in Portugal. That’s the pipe into Germany and the rest of regulated Europe without spending years certifying a Vancouver site.
• Net loss still about $0.7M, flat vs last year, but G&A included non-recurring IR spend tied to the Q4 financing. Strip that plus interest and non-cash and they called Q2 roughly break-even on an adjusted basis.

The call they already made:

On the Q2 release they guided positive quarterly adjusted EBITDA and operating cash flow on a consistent basis starting Q3 2026, if medical and export targets hold. Q3 closed September 30. The print is the next catalyst, not a story for next year. If they hit what they said, this stops being a turnaround narrative and becomes the first clean profitable quarter of the new mix.

Tape:

Canadian side is no longer dead. Average CSE volume has been sitting around 90k, and late September printed real days: about 250k on Sep 18, 189k on Sep 23, 359k on Sep 25. Several times a quiet session, on a name that used to trade in dribs and drabs. Still a 3-cent stock. Still illiquid. But the Canadian book is picking up into the quarter they said would be the inflection.

Why this can rerate:

Q4 2025 was the volume peak ($6.2M gross, $4.1M net, slightly positive Adj. EBITDA). H1 2026 is the mix quarter. Revenue is not beating that Q4 print and nobody should pretend it is. What is beating the old book is quality. Medical 2x. Exports back. Margin almost doubled year over year. House brands (Happy Hour BCLDB listings, Chomp, Northern Drip) instead of third-party consignment.

The bull case from here is simple. Veteran medical keeps compounding off a $2.2M run rate into a VAC reimbursed market that is still underpenetrated. Exports scale through the Portugal EU-GMP partner. Q3 prints the positive Adj. EBITDA and operating cash flow they just guided, and that quarter is already done. At a roughly $3–4M market cap, you are not paying for any of that. You are paying for the old rec story. If CSE volume keeps building, this doesn’t need a lot of dollars to move.

Risks stay in the post. Balance sheet as of Q1 was still payable-heavy (about $3.7M A/P), cash was thin, working capital was negative, and the going-concern language has not gone away. Guidance is not a result. Q3 has to show up in cash, not just margin. Germany is also getting stricter on late-stage GMP washing, which is why the Portugal partner matters more than a pack-room story.

Microcap, illiquid, but todays volume says otherwise can go to zero. But they told the market Q3 would be the profitable quarter, and that quarter just finished.

Markets are moving on-chain. Perps already made that trip. They started as a way to trade with leverage around the clock, became the default, and on Hyperliquid they spread to stocks, indexes, oil, and companies that are not even public. Options are next. They are already the main event in traditional markets, and they barely exist on-chain.

Jake Sylvestre, founder of Hypercall, laid this out in Financial Tech Times on October 2. S&P 500 index options averaged 4.6 million contracts a day in August, more than $3 trillion of notional. Every on-chain options venue combined did about $4.4 billion over the last 30 days. The S&P trades that in about 30 seconds. Over the past year, on-chain options did about $19.5 billion, and last month’s pace annualizes to more than $50 billion. Almost all of that is still the two biggest coins. Equity and index options, the actual market, have barely started.

The flow underneath is already there. Hyperliquid is doing about $2.2 billion a day in perps on oil, the S&P 500, Nvidia, and other traditional assets. Options on those underlyings are a far bigger market. On-chain, that book has barely opened.

Orange is Derive, and it is most of the book from November 2025 through September 2026. White is Rysk, cyan is Paradex, purple is Aevo, teal is Hypersurface. Hypercall is green. It is a rounding error through the summer, then it is the cap on the September bar. Left axis tops at $6 billion. September is the only month through $4 billion. September notional across the whole tape was $4.829 billion, up 121.7% from August. The line on the right axis, running toward $21 billion, is the cumulative path, not one month.

Sylvestre’s own figures match that band. Hypercall launched June 1. Since then: $592 million notional, $536 million of it in September, a recent week at about $60 million a day. He calls that the largest on-chain equity options venue. He also calls it a rounding error. $60 million a day is under 1% of a normal Hyperliquid day, and about 0.002% of daily S&P options notional. The gap is the bull case.

Marlon at https://x.com/momilio/status/2105714263784579302 had the outside number: Hypercall notional went from $9.4 million in August to $538.8 million in September, about 57x, and ranked second for the month behind Derive. Some of that was a short-dated bear put spread whose market maker hedged on Hyperliquid and accounted for 15% of all S&P perp volume on HL that day. That is the product working as designed.

Why this one, and not another options app

Earlier on-chain options venues died for one reason. Anyone short an option needs a cheap, liquid hedge. That hedge did not exist for stocks, indexes, or oil. Hyperliquid’s perps fill it: same underlying, same USDC collateral, open every hour. Hypercall is built into that stack. Makers hedge S&P and single-stock options there, including on weekends. It is the options book using Hype’s liquidity as the hedge, not a separate venue hoping liquidity shows up later.

A perp can get liquidated on a Sunday gap even if the trade is right by Monday. An option buyer knows the max loss going in. That is the premium. The longer markets stay open, the more that matters. Earnings hit after the bell. Macro prints on weekends. On August 26, the day Nvidia reported, Nvidia options on Hypercall did about $554,000, against under $10,000 a day the week before. Two days ahead of Micron earnings, Micron options did about $7.4 million. SpaceX options do not trade anywhere else.

Live since launch: S&P 500, Nvidia, Micron, Apple, Microsoft, Meta, Alibaba, SanDisk, SpaceX, plus BTC and ETH.

https://x.com/MorningWoodRsch/status/2107096653635129848

Last 30 days the tape is $5.66 billion. Derive is still 78.7%. Hypercall is the green slice at 10.1%, ahead of Paradex at 7.5%, Rysk 2.6%, Aevo 1.1%. Second place, one quarter after launch, on a book that was basically one venue a month ago.

That is the setup the public companies are positioning into. One wants to be the listed treasury. One wants to be the premium seller.

$SONI: leading to be the Hypercall DAT

SonicStrategy (CSE: SONI, OTCQB: SONIF) is out in front to be the public DAT for Hypercall. Same playbook as the other treasury names, different asset. Instead of sitting on a base-layer coin, it is accumulating SYN, the asset tied to Synapse Labs, which is building the options venue. If Hypercall becomes the on-chain equity options book, SONI is trying to be the stock you own to get that exposure without running the venue yourself.

• September 23: 500,000 SYN at about US$0.23, roughly US$115,000. First treasury buy aimed at on-chain derivatives. Company cited a US$57.5 million fully diluted value at the print.
• September 24: another 260,000 at about US$0.1923, roughly US$50,000. Total about 760,000 SYN. Combined cost about US$165,000.
• CEO Dustin Zinger framed it as the treasury moving into derivatives as more real-world assets trade around the clock, and said the firm intends to keep expanding that book.
• Synapse has proposed sending 70% of certain protocol fees to SYN buybacks. Not approved. Not live. If it clears, venue activity and demand for the treasury asset start to rhyme, which is the whole point of a DAT.

The position is small next to a real treasury strategy. The seat is not. Nobody else public is positioned as the listed wrapper on Hypercall. SONI bought the stub in the same month the green band showed up, and it is the only CSE name marketing itself as that exposure. That is how these wrappers start: a small open-market position, a filing that names the venue, then a raise if the tape keeps going. September 22 it already had a proposed private placement of up to C$4.5 million on the board.

$LUXX: the one that wants to trade it

Luxxfolio (CSE: LUXX, OTCQB: LUXFF) is the other side of the same trade. It does not want to own the builder. It wants to use the venue. October 5 release. Non-binding letter of intent dated October 4.

• Proposed program: sell covered calls through Hypercall on part of the treasury and book the premium as a second revenue line next to operations.
• Premium is meant as extra capital for the existing accumulation strategy, subject to how the program actually performs and what the treasury needs.
• Hypercall’s side of the LOI: fast-track product support, arrange market makers and liquidity, and handle onboarding and access.
• CEO Tomek Antoniak: build that secondary revenue stream, then look at payout options and extra functionality for pool participants once the commercial terms exist.
• No closed facility, no disclosed notional, no strike grid. An LOI does not pay premium.

The positioning still matters. A listed company is asking to be a covered-call seller on a 24/7 options book, in the same month that book took 10% of on-chain notional share. If the program lists, LUXX is not a spectator. It is flow. SONI is the equity stub on the stack. LUXX is the corporate user of the product. Public markets usually get one of those first. Here they showed up together.

That is the split. SONI is leading as the Hypercall DAT. LUXX wants to sell premium on the venue itself. Both landed in the same window the green band showed up. Options are moving on-chain, Hypercall is the book wired into Hype’s liquidity, September is when the volume inflected, and two listed companies are already choosing a side: own the builder, or trade the venue.

Not advice. The SONI position is about US$165,000. The LUXX piece is non-binding. The volume is still nothing next to listed S&P options. This is the start of the curve, not a finished market.

Netlist is one of the very few companies in the world to have secured a billion-dollar agreement after nearly six years of legal battles, and this is just the beginning.

“Samsung Ends Patent Dispute With $897 Million Deal, Signs Five-Year Strategic Agreement With Netlist.
Samsung will sell $1.5b memories to netlist in 5 years too”.

Let me now return to explaining a simple concept. The DRAM market has exploded in recent years, and according to analysts and investment banks, it could reach $2 trillion by 2030, driven by HBM, MRDIMM, CXL, DDR5, and other technologies.

Let me now return to explaining a simple concept. The DRAM market has exploded in recent years, and according to analysts and investment banks, it could reach $2 trillion by 2030, driven by HBM, MRDIMM, CXL, DDR5, and other technologies.

Netlist and SK signed an agreement involving $40 million and $600 million worth of memory products to be used in selling their technology.
SK leveraged this deal to generate tens of billions in profits while spending virtually nothing.
The agreement expired in April 2026, and while a new deal is not yet in place, CEO Hong has confirmed that the two companies maintain an excellent relationship and that supply volumes continue to grow; this implies that the SK deal is ready, but they are waiting for the Micron deal to be finalized first.

Samsung reached a settlement in August, leaving Micron standing alone.
Netlist recently initiated two ITC investigations; while costly, they have the potential to halt sales of all Micron DRAM products. This development caused quite a stir and generated significant hype around Netlist—it was even trending on StockTwits for weeks.

Based on emerging details, the deal with SK must be finalized by April 2027. Netlist is currently pressuring Micron on all fronts, which could signal a second deal in the coming weeks or months.
Netlist could potentially become a billion-dollar company in cash alone, while also generating massive annual profits from IP licensing.
Samsung paid $240 million in cash plus $130 million annually for IP licenses—which represents 100% profit!

Netlist has spent over $250 million on legal fees over the past six years and could now make history with three agreements and the launch of revolutionary products such as CXL NVvault and LP (low-power) MRDIMM.
Netlist utilizes a DRAM foundation and customizes its product with superior technology that saves energy, boosts performance, and delivers better results.

Netlist is about to write a unique chapter in history, just like Rambus did over 13 or 14 years ago!

I know a little bit about trading, I originally started back in 2022 right after graduating high school and then I opened up a Roth IRA a few months into my freshman year of college. I’ll throw a little money into it here and there, but for the most part I’ve got safe options in there.

For my birthday I got some money and decided, to hell with it, and bought 1,000 shares of FLYYQ. I know they’re completely screwed and bankrupt, but I’m a glass half full kind of person.

If anyone has bought shares, are you still holding? Do you have any regrets? I’d like to get some new insights.

​Recently a fellow Investor recommended to put this "We Make Life Better" company on your watchlist. here are some more info.

ViaCLYR moved into full commercial-launch mode in August and two new distribution partners have recently signed on.

https://preview.redd.it/4llvf2y6glth1.png?width=2052&format=png&auto=webp&s=a9a150739a646bf781be7c946eece28ad389e8d8

The distribution setup now covers:

• Advanced Solutions: U.S. commercial channel, including wound-care clinics, physicians and health systems.

• Al-Hikma: exclusive international distribution across the Middle East, North Africa and adjacent markets—an 18-country opportunity.

• Spartan Medical: U.S. government-healthcare access through DLA ECAT, including VA, DoD and other federal buyers.

Stocking orders from each are expected within the next months.

ViaCLYR Tech Video in comments.

BioClynse, the surgical-irrigation product based on the same Clyrasept platform, is next - it will be launched co branded by a top 4 global medical leader ($100 billion plus market cap)

ViaCLYR clinical/technical facts:

https://preview.redd.it/2iu41y8zglth1.png?width=1798&format=png&auto=webp&s=9856ca21af5b41f8659551f235bcfae083178b4f

• FDA 510(k)-cleared

• Copper-iodine complex technology

• Non-cytotoxic and tissue-safe

• No rinse required

• Company testing: 99.9999% kill of 18 pathogens in one minute

• Includes MRSA, VRE and C. auris

• Reported 72-hour antimicrobial activity

BioClynse - the surgical-irrigation product built on the same platform - is getting closer.

​Clyra has prepared for potential capacity ramp-up to 2 × 1 million units annually, reportedly a requirement before the national distribution arrangement was signed.

The alignment is notable: BioLargo CEO Dennis Calvert invested ~ $250K directly into Clyra, while Clyra CEO Steve Harrison also put in a significant personal amount.

Pre launch value of Clyra ~$100 million 

Post successful launch value expected ~ $500 million - $1B

The approximately $100M Clyra valuation was based on actual cash investments by outside investors, not simply an internal mark.

BioLargo Owns 48% of Clyra Medical PLUS BioLargo is entitled to a 6% worldwide royalty on Clyra’s gross sales

With BLGO’s market cap below $30 million, its 48% stake in Clyra Medical alone - based on Clyra’s roughly $100 million valuation- appears to be worth more than BioLargo’s entire market cap, before royalties.

​But there is much more to come at BioLargo:

https://preview.redd.it/ruw5yawdglth1.png?width=2088&format=png&auto=webp&s=467d5226fd1891495abbe7bf058ffba3c2b4b248

​Here a quote I've found by Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy, Christus Santa Rosa Hospital System; Co-founder and Chief Medical Officer, Wound Centrix LLC

"My experience with CICS in more than 50 patients has convinced me that this is a disruptive innovation. Effect duration is likely key to the effects I’m seeing, and which I reported on at The Boswick Symposium. Hypochlorous has a half-life measured in seconds, while available data already underscores durable CICS effects at 72 hours, and as evidence accumulates, I predict that this will become the preferred wound cleanser. I’ve not seen the granulation quality improvements, sinus tract volume reduction, and favorable edge effects, with hypochlorous that I see regularly with CICS. Frankly, the differences are stark."

Don't believe me!

Ask surgeons, wound-care clinicians and infection-control contacts: if these results translate into routine use, could ViaCLYR/BioClynse be a surgical workflow game changer- and could a global distribution leader be the vehicle to bring BioClynse to market at real scale?

BLGO is sitting near all-time lows yet they are getting closer and closer to mayor revaluation events that could come by surprise.

If BioLargo executes on even a few of these opportunities, I think the upside from these levels is fascinating. If it fails to execute, the downside and dilution risk remain very real.

Read the filings. Read the bull case. Read the bear case. Check every number. Then decide for yourself. Certainly worth to add to your watchlist.

Not financial advice. I own BLGO shares and recently added $45,000.



https://preview.redd.it/4cvl6gdpglth1.png?width=680&format=png&auto=webp&s=b7b7e37a6fb1ab96bd9857a55c14cf5e6bf7b30b

If you have been following my profile, you are probably familiar with my style of trading penny stocks, which involves scanning for stocks which have been beaten down and are about to move, fueled by company issued BS press releases, or trading momentum for one reason or another.

The proper risk management when trading these stocks is to diversify into about 5 stocks, which are seemingly uncorrelated. The issue is that when the general stock market risk is OFF, then the correlation increases among penny stocks and they become one of the least desirable assets, so those 5 stocks might be drawing down nearly equally as having a single stock. This fact, along with certain the trends which have emerged after the PDT removal are presenting us with unique opportunities in momentum penny stock trading.

Without spelling out the specifics, I will run an experiment/challenge where I use my new scanner each day for the most promising stocks, and pick up to 5 of them, but often 1 or 2, and aim to get in before the crowd and get out before they run for the exits, while rolling the capital and remaining fully invested.

This will be a similar but different experiment from my "Ten Doublings" challenge, where I aim to find only 2X stocks and not settle for less than 100% gains. In this challenge I will keep the duration short, and the aim will be to close the trades the same day or the next day. What used to happen over weeks and months with swing trading can now be compressed in day trading, thanks to the regulators who got rid of the PDT rule, AI automation, and people just being people when it comes to trading psychology.

Stay tuned for my trades, and ask any questions which you may have. Good luck if you choose to trade the same or similar trades, and keep in mind that these my trades only, for educational purposes, and that you need to do your own research and formulate your own trades.

Cheers!

PS: This is will likely be my last reddit challenge before I ride into the sunset. My health is not great and I have a family to care for, so this challenge contains "yolo" intentionally and appropriately.

SLI has dropped to 52-week lows of $1.73 and could represent a good opportunity to buy at an attractive price. Within the last few days several Company Executives have executed informative buys of nearly 100,000 shares.

Downward pressure seems to be mainly driven by pressure from China and continued lack of profitability. At a recent investor conference SLI highlighted strong project economics, government support and long-term demand growth.

The company seems confident that their key Southwest Arkansas project will receive funding by end of 2026 allowing them to officially begin construction and a path towards profitability.